The estimated Net Worth of Leonard L Mazur is at least $6.03 Milion dollars as of 27 September 2019. Mr Mazur owns over 2,234,700 units of Citius Pharmaceuticals Inc stock worth over $5,435,332 and over the last 9 years he sold CTXR stock worth over $0. In addition, he makes $592,917 as Exec. Chairman & Sec. at Citius Pharmaceuticals Inc.
Mr has made over 8 trades of the Citius Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 2,234,700 units of CTXR stock worth $2,011,230 on 27 September 2019.
The largest trade he's ever made was buying 5,000,000 units of Citius Pharmaceuticals Inc stock on 30 March 2016 worth over $3,000,000. On average, Mr trades about 726,471 units every 75 days since 2016. As of 27 September 2019 he still owns at least 10,255,343 units of Citius Pharmaceuticals Inc stock.
You can see the complete history of Mr Mazur stock trades at the bottom of the page.
Leonard L. Mazur is the Exec. Chairman & Sec. at Citius Pharmaceuticals Inc.
As the Exec. Chairman & Sec. of Citius Pharmaceuticals Inc, the total compensation of Mr Mazur at Citius Pharmaceuticals Inc is $592,917. There are 2 executives at Citius Pharmaceuticals Inc getting paid more, with Myron Z. Holubiak having the highest compensation of $1,475,625.
Mr Mazur is 76, he's been the Exec. Chairman & Sec. of Citius Pharmaceuticals Inc since . There are 1 older and 11 younger executives at Citius Pharmaceuticals Inc. The oldest executive at Citius Pharmaceuticals Inc is Suren Dutia, 77, who is the Independent Director.
Leonard's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ, 07016.
Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over $0 worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth $15,819,221 . The most active insiders traders include Leonard L Mazur, Myron Z Holubiak oraz Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of $523,934. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth $48.
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include: